Abstract
Tumour necrosis factor (TNF) has a central role in the pathogenesis of psoriatic arthritis (PsA). Adalimumab (Humira®, Abbott Laboratories) is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF. Adalimumab blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. In clinical trials of patients with PsA, adalimumab significantly reduced both joint and skin symptoms. In addition, structural changes were inhibited, and statistically and clinically significant improvements in measures of disability and quality of life were observed. Adalimumab was generally safe and well tolerated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
